Form 4: Regulus Therapeutics Director Pascale Witz Reports Acquisition of Restricted Stock Units
SEC Form 4 Filing
Director Pascale Witz reports the acquisition of 62,500 restricted stock units in Regulus Therapeutics.
Summary
- On April 30, 2025, Pascale Witz, a director of Regulus Therapeutics Inc., reported the acquisition of 62,500 restricted stock units.
- These units vest in equal monthly installments over 12 months from the grant date.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock unit acquisition, which doesn't inherently indicate positive or negative sentiment.
Positives
- The acquisition of restricted stock units by a director could be seen as a positive sign of confidence in the company's future.
Industry Context
Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers, which can be informative for investors.
Stakeholder Impact
- Shareholders may view the acquisition of restricted stock units by a director as a sign of confidence in the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 04/30/2025 | Date of earliest transaction: Pascale Witz granted 62,500 Restricted Stock Units. |
Keywords
Regulus Therapeutics, Director, Pascale Witz, Restricted Stock Units, RGLS, Form 4, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.